By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Astellas Pharma Inc. 

3-11 Nihonbashi-Honcho 2-chome

Chuo-ku  Tokyo  103-8411  Japan
Phone: 81-3-3244-3000 Fax: 81-3-3244-3272





Gilead (Durham, NC) 

Company News
Astellas Pharma Inc. (ALPMY) Broadens Regional Leadership And Creates New Corporate Affairs And Corporate Development Functions 2/20/2015 8:39:37 AM
Astellas Pharma Inc. (ALPMY) Launches The Newest Element In Its Global Corporate Brand Campaign On CNN's Global Broadcast Network 2/16/2015 11:39:06 AM
Astellas Pharma Inc. (ALPMY) Broadens Commitment to Clinical Trial Data Transparency 2/2/2015 11:06:37 AM
Astellas Pharma Inc. (ALPMY). Immunomic Therapeutics Forge $70 Million Vaccine Pact 1/30/2015 6:28:48 AM
Astellas Pharma Inc. (ALPMY) Announces FDA Anti-Infective Drugs Advisory Committee Recommends Approval Of CRESEMBA┬« (Isavuconazonium) For Treatment Of Invasive Aspergillosis And Mucormycosis 1/23/2015 7:03:11 AM
FDA Panel Backs Astellas Pharma Inc. (ALPMY)'s CRESEMBA for Invasive Fungal Infections 1/22/2015 7:36:47 AM
Astellas Pharma Inc. (ALPMY) Hires Global Executive Eric Terhaerdt To Lead Global Development Operations 1/15/2015 9:58:50 AM
SSF's Cytokinetics, Inc. (CYTK) Snags $675 Million+ Deal With Astellas Pharma Inc. (ALPMY) 12/23/2014 6:21:33 AM
Astellas Pharma Inc. (ALPMY) Release: Data Presented From Phase 2 Study Of Enzalutamide In Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer 12/15/2014 10:41:27 AM
Medivation, Inc. (MDVN) And Astellas Pharma Inc. (ALPMY) Phase 3 PREVAIL Trial Named Clinical Advance Of The Year By SCRIP 12/12/2014 11:04:46 AM